The CenterWatch Monthly, March 2011
CROs tackling investigative site success
Developing strategic partnerships, adding more support, resources
As CROs become more actively involved in all aspects of study conduct, drug sponsors increasingly rely on them to select investigative sites to conduct their clinical trials. To meet those expectations, CROs are using various strategies to develop stronger relationships with top-performing sites and improve the chance of investigative site success.
Global CROs are developing strategic partnerships with sites, using performance-based metrics in site selection and...
Sites wrestle with rise in study delays and cancellations
Increase has sites grappling with patient care, financial losses
Delays and cancellations have plagued the clinical trials industry since its inception, causing a trickle-down loss to all parties involved. In any particular trial, the loss starts at the sponsor level and flows down to the CRO and any vendors supporting the trial, such as electronic data capture companies, patient recruitment firms, web portal designers and media outlets.
But some say the investigative sites shoulder the hardest blow in these situations. After all, they have engaged in months of time-consuming start-up activities and employee scheduling. And among all vendors, they tend to...
Eye On Amgen
Amgen is a biotechnology company in human therapeutics, with more than 25 years of experience. Utilizing advances in recombinant DNA, cellular and molecular biology, Amgen developed the first new products in this field to improve health in people with cancer, renal disease, rheumatoid arthritis, bone disease and other serious conditions.
To read the full articles for this issue or for more information on these and other breaking stories, please click here for subscription information.